ENGERIX-B PEDIATRIC/ADOLESCENT Rx
Generic Name and Formulations:
Hepatitis B vaccine (recombinant) 10mcg/0.5mL; aluminum hydroxide adsorbed; IM inj; preservative-free; contains thimerosal (trace).
Indications for ENGERIX-B PEDIATRIC/ADOLESCENT:
Hepatitis B immunization.
Give IM in deltoid muscle. 11–19yrs: 10mcg at elected date and repeat 1 and 6 months later, or 20mcg at elected date and repeat 1, 2, and 12 months later, or 20mcg at elected date and repeat 1 and 6 months later. >19yrs: 20mcg at elected date and repeat 1 and 6 months later, or 20mcg at elected date and repeat 1, 2, and 12 months later. Hemodialysis: 40mcg at elected date and repeat 1, 2, and 6 months later. High-risk: consider hepatitis B immune globulin also. Booster dose: when appropriate, may use 20mcg for persons 11yrs of age and older; hemodialysis patients booster dose is 40mcg.
Give IM in anterolateral thigh or deltoid; see literature. Infants (mothers are HBsAG negative): 10mcg at birth and repeat 1 and 6 months later; infants (mothers are HBsAG positive) and children through age 10yrs: 10mcg at elected date and repeat 1 and 6 months later, or 10mcg at elected date and repeat 1, 2, and 12 months later. High risk: consider hepatitis B immune globulin also. Booster doses: when appropriate, may use 10mcg for children age 10yrs or younger, or 20mcg for ages 11yrs and older.
May defer in acute febrile illness or active infection. May be given SC only if risk of hemorrhage. Have epinephrine inj available. Multiple sclerosis. Pregnancy (Cat.C). Nursing mothers.
Local reactions, malaise, nausea, diarrhea, rash. Anaphylaxis.
Pediatric/Adolescent (single-dose prefilled Tip-Lok syringe)—5 (without needles); Pediatric/Adolescent (single-dose vials)—1, 10; Adult (single-dose prefilled Tip-Lok syringe)—5 (without needles); Adult (single-dose vials)—1, 10, 25
Neurology Advisor Articles
- Clarifying Cardiovascular Risk in Migraine
- More Evidence Supports Benefits of Cannabidiol for Treatment-Resistant Epilepsy
- Parkinson Disease Symptom Fluctuations Well-Managed With Adaptive Deep Brain Stimulation
- Monthly Erenumab Reduces Frequency of Episodic Migraine
- Female Gender, Natalizumab Exposure Associated With Increased Lymphopenia Risk in FNG-Treated MS
- Tamsulosin Associated With Dementia Risk in Older Patients With BPH
- Gait Difficulty in Parkinson Disease May Be Associated With More Progressive Disease Course
- Tau PET a Useful Biomarker for Alzheimer Disease Risk and Progression
- Multiple Sclerosis Drug Zinbryta Withdrawn From the Market
- Predicting Seizure Risk Following Ischemic Stroke With SeLECT Score
- Surgical Outcomes Associated With Trigger Site Deactivation for Migraines
- Combined Exercise Training Increases BDNF in Relapsing-Remitting MS
- Exome-Targeted Capture Sequencing Can Diagnose Previously-Undetected Ataxia
- Strategies for Preventing and Treating Delirium
- High Total Cholesterol Neuroprotective Against Cognitive Decline